Loading...
Despite the introduction of many new cancer therapies during the last decade, outcomes for most patients with metastatic breast cancer have not changed significantly: Median survival remains about 2 years. Nonetheless, novel agents continue to be developed with the goal of extending survival for patients with advanced disease. In the phase III EMBRACE trial, researchers evaluated eribulin mesylate (a synthetic analogue of the mitotic inhibitor halichondrin B) versus treatment of physician's choice in 762 patients with metastatic breast cancer (20% with triple-negative disease) who were previously treated with an anthracycline and a taxane. This trial is unique among studies of agents for metastatic breast cancer because, rather than concent…